Previous 10 | Next 10 |
AgeX Therapeutics , Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on November 22, 2022 it received notification from the staff of the NYSE American (the “Exchange”...
AgeX Therapeutics press release ( NYSE: AGE ): Q3 GAAP EPS of -$0.06. Revenue of $9M (-62.5% Y/Y). For further details see: AgeX Therapeutics GAAP EPS of -$0.06, revenue of $9M
AgeX Therapeutics press release ( NYSE: AGE ): Q2 GAAP EPS of -$0.07. Revenue of $0.01M (-75.0% Y/Y). Cash, and cash equivalents, and restricted cash totaled $0.8 million as of June 30, 2022. Shares -12.82% . For further details see: AgeX Therapeutics...
AgeX Therapeutics , Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended June 30, 2022. Liquidity and Capital Resources During...
AgeX Therapeutics , Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that Dr. Joanne Hackett has been appointed Chairperson of AgeX’s Board of Directors. Dr. Hackett joined the B...
AgeX Therapeutics press release (NYSE:AGE): Q1 GAAP EPS of -$0.07. Cash, and cash equivalents, and restricted cash totaled $0.5 million as of March 31, 2022. Since April 1, 2022, AgeX has received an additional $1 million of cash through a loan from Juvenescence. For further details see: ...
AgeX Therapeutics , Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended March 31, 2022. Liquidity and Capital Resources 202...
Gainers: Avadel Pharmaceuticals (AVDL) +30%. AgeX Therapeutics (AGE) +9%. Helius Medical Technologies (HSDT) +7%. Quipt Home Medical (QIPT) +7%. Gamida Cell (GMDA) +5%. Losers: Protagonist Therapeutics (PTGX) -47%. Nkarta (NKTX) -14%. ...
AgeX Therapeutics press release (NYSE:AGE): FY GAAP EPS of -$0.23. Revenue of $0.14M (-61.1% Y/Y). For further details see: AgeX Therapeutics GAAP EPS of -$0.23, revenue of $0.14M
Signed research collaboration with University of California, Irvine, on research program for exosome-based therapies for certain brain disorders Licensee ImStem Biotechnology announced first U.S. multiple sclerosis patient dosed with IMS001 AgeX Therapeutics , In...
News, Short Squeeze, Breakout and More Instantly...
Shares of Serina to commence trading on NYSE American under the ticker symbol “SER” on March 27, 2024 Lead candidate SER-252, POZ-apomorphine preclinical studies anticipated to be completed in the fourth quarter of 2024; IND submission to the FDA for the initiation of a Phas...
ALAMEDA, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended Decembe...
A look at the top 10 most actives in the United States Verb Technology Company Inc. (VERB) rose 211.4% to $0.4422 on volume of 532,901,553 shares Fisker Inc. Class A (FSR) rose 12.8% to $0.1747 on volume of 376,460,729 shares Better Therapeutics Inc. (BTTX) rose 27.4% to $0.0446 on volume...